Tolvaptan
- Generic Name
- Tolvaptan
- Brand Names
- Jinarc, Jynarque 45/15 Carton, Samsca, Tolvaptan Accord, Xeljanz
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25ClN2O3
- CAS Number
- 150683-30-0
- Unique Ingredient Identifier
- 1E2497LPNY
- Background
Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
- Indication
Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.
- Associated Conditions
- Autosomal Dominant Polycystic Kidney Disease （ADPKD), Symptomatic euvolemic Hyponatremia, Symptomatic hypervolemic Hyponatremia
- Associated Therapies
- -
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- Conditions
- Interventions
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 15
- Registration Number
- NCT03274076
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload
- Conditions
- Interventions
- First Posted Date
- 2017-08-21
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03255226
Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- Hanyang University
- Target Recruit Count
- 378
- Registration Number
- NCT03011281
- Locations
- 🇰🇷
Hanyang University, Seoul, Korea, Republic of
Study of Tofacitinib in Refractory Dermatomyositis
- First Posted Date
- 2016-12-26
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 10
- Registration Number
- NCT03002649
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 269
- Registration Number
- NCT02996500
- Locations
- 🇺🇸
Arthritis & Rheumatic Care Center, South Miami, Florida, United States
🇺🇸Medical Associates of North Georgia, Canton, Georgia, United States
🇺🇸Millennium Research, Ormond Beach, Florida, United States
Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
- Conditions
- Interventions
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2023-01-03
- Target Recruit Count
- 91
- Registration Number
- NCT02964273
Tolvaptan for Advanced or Refractory Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 9
- Registration Number
- NCT02959411
- Locations
- 🇨🇦
University of Calgary, Calgary, Alberta, Canada
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 1672
- Registration Number
- NCT02847624
- Locations
- 🇯🇵
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
Efficacy of Tolvaptan on ADPKD Patients
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2020-06-05
- Lead Sponsor
- Kyorin University
- Target Recruit Count
- 118
- Registration Number
- NCT02729662
- Locations
- 🇯🇵
Kyorin University Hospital, Mitaka, Tokyo, Japan
Regional Tolvaptan Registry
- Conditions
- Interventions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Cardiology Research UBC
- Target Recruit Count
- 25
- Registration Number
- NCT02666651
- Locations
- 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.